Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant.

Clinical and experimental dermatology - 1 Oct 2021

Charvet E, Bourrat E, Hickman G, Donadieu J, Bellanné-Chantelot C, Jachiet M, Bouaziz J-D, Bagot M, Cassius C

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to CARD Signaling Adaptor Proteins
Share to Dermatitis, Atopic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanylate Cyclase

Share to Injections, Subcutaneous

Share to Interleukin-4 Receptor alpha Subunit

Share to T-Lymphocytes, Helper-Inducer

Share to Th2 Cells

Source

Identifiers

PMID: 33864281
DOI: 10.1111/ced.14686

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant.PMID 33864281Read ↗

Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 PatientsSemantic proximity Read ↗

Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.Semantic proximity Read ↗

Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy.Semantic proximity Read ↗

New pathogenic and therapeutic paradigms in atopic dermatitis.Semantic proximity Read ↗

Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report.Semantic proximity Read ↗

Germline hypomorphic CARD11 mutations in severe atopic diseaseSemantic proximity Read ↗

Ancestry-associated immune signalling differences in atopic dermatitis and dupilumab treatmentSemantic proximity Read ↗

Effectiveness of dupilumab in pediatric patients with a nummular phenotype of atopic dermatitis.Semantic proximity Read ↗

Pediatric IPEX-Associated Dermatitis Responds To Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling.Semantic proximity Read ↗

Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.Semantic proximity Read ↗

Impact of dupilumab and upadacitinib treatment on epigenetic and transcriptomic alterations in skin-homing T cells of atopic dermatitis patientsSemantic proximity Read ↗

Clinical phenotypes of adult atopic dermatitis and related therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.